These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22143524)

  • 1. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.
    Bhavnani SM; Rubino CM; Hammel JP; Forrest A; Dartois N; Cooper CA; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1065-72. PubMed ID: 22143524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.
    Rubino CM; Bhavnani SM; Forrest A; Dukart G; Dartois N; Cooper A; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2012 Jan; 56(1):130-6. PubMed ID: 21968360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
    Crandon JL; Banevicius MA; Nicolau DP
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1165-9. PubMed ID: 19114676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.
    Passarell JA; Meagher AK; Liolios K; Cirincione BB; Van Wart SA; Babinchak T; Ellis-Grosse EJ; Ambrose PG
    Antimicrob Agents Chemother; 2008 Jan; 52(1):204-10. PubMed ID: 17954694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
    Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
    Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.
    Ambrose PG; Hammel JP; Bhavnani SM; Rubino CM; Ellis-Grosse EJ; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1466-70. PubMed ID: 22155834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
    Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
    Meagher AK; Passarell JA; Cirincione BB; Van Wart SA; Liolios K; Babinchak T; Ellis-Grosse EJ; Ambrose PG
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1939-45. PubMed ID: 17353238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
    Bhavnani SM; Rubino CM; Ambrose PG; Babinchak TJ; Korth-Bradley JM; Drusano GL
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1207-12. PubMed ID: 20038623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
    Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
    J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
    Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
    Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
    [No Abstract]   [Full Text] [Related]  

  • 15. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
    Schafer JJ; Goff DA; Stevenson KB; Mangino JE
    Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
    Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
    Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
    Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging trends of nosocomial pneumonia in intensive care unit of a tertiary care public teaching hospital in Western India.
    Bhadade R; Harde M; deSouza R; More A; Bharmal R
    Ann Afr Med; 2017; 16(3):107-113. PubMed ID: 28671150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
    Koomanachai P; Crandon JL; Banevicius MA; Peng L; Nicolau DP
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5060-3. PubMed ID: 19738006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
    Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.